Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
SUPN Stock Predictions and Ratings
WSX Rating:
BUY
WSX Forecast (1yr):
14.80%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
39.20%
SUPN Stock Analysis
SUPN
PE Ratio:
SUPN
PEG Ratio:
SUPN
Forward EPS Growth (12 month):
84.10%
SUPN
PS Ratio:
3.3
SUPN
PSG Ratio:
0.2
SUPN
Forward Revenue Growth (12 month):
17.30%
SUPN Articles
No data was found